Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia

BJU International, Supplement

Volumn 101, Issue SUPPL.4, 2008, Pages 8-15

  Pastorekova, Silvia ^a   Ratcliffe, Peter J ^b   Pastorek, Jaromir ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE IX INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY M75; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SULFONAMIDE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL HYPOXIA; CELL PH; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REGULATION; GLYCOLYSIS; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; PH; PHYSIOLOGY;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL HYPOXIA; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 44449091556     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47
2. Ratcliffe PJ. Understanding hypoxia signalling in cells - a new therapeutic opportunity? Clin Med 2006; 6: 573-578
3. Coleman ML, Ratcliffe PJ. Oxygen sensing and hypoxia-induced responses. Essays Biochem 2007; 43: 1-15
4. Belaiba RS, Bonello S, Zähringer C etal. Hypoxia up-regulates hypoxia-inducible factor-la transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007; 18: 46917
5. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A. Akt 1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4: 471-479 (Pubitemid 44197042)
6. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001 ; 21: 3995-4004 (Pubitemid 32476461)
7. Wenger RH. Mitochondria: oxygen sinks rather than sensors? Med Hypotheses 2006; 66: 380-383
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
9. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007; 117: 862-865
10. Lau KW, Tian YM, Raval RR, Ratcliffe PJ, Pugh CW. Target gene selectivity of hypoxia-inducible factor-a in renal cancer cells is conveyed by post-DNAbinding mechanisms. Br J Cancer 2007; 96:1284-1292
11. Löfstedt T, Fredlund E, HolmquistMengelbier L et al. Hypoxia inducible factor-2α in cancer. Cell Cycle 2007; 6: 919-926
12. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxiainducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 567586
13. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Concerte2006; 66: 8927-8930
14. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68-72
15. Brahimi-Horn MC, Pouysségur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 2007; 43: 165-178
16. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899
17. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27: 7381-7393 (Pubitemid 350033646)
18. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185 (Pubitemid 43316523)
19. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 2000; 6: 15-19 (Pubitemid 30010232)
20. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004; 14: 267-274 (Pubitemid 38903231)
21. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-795
22. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 1997; 15: 382-392 (Pubitemid 27285811)
23. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002; 8: 1284-1291 (Pubitemid 35177386)
24. Karumanchi SA, Jiang L, Knebelmann B, Stuart-Tilley AK, Alper SL, Sukhatme VP. VHL tumor suppressor regulates CI-/HC03-exchange and Na+/ H+ exchange activities in renal carcinoma cells. Physiol Genomics 2001; 5: 119-128
25. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL HIF-1 regulates hypoxic induction of NHE1 expression and alkalinisation of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 2006; 291 : L941-9
26. Ullah MS. Davies AJ. Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem 2006; 281: 9030-9037
27. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003; 76: S11-22 (Pubitemid 39530312)
28. Supuran CT. Carbonic anhydrases. Catalytic mechanisms, distribution and physiological roles. In Supuran CT, Scozzafava A, Conway J eds, Carbonic Anhydrase: Its Inhibitors and Activators. Boca Raton-London-New YorkWashington, DC: CRC Press, 2004: 1-24
29. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229 (Pubitemid 39004275)
30. Pastorek J, Pastorekova S, Callebaut l et al. Cloning and characterisation of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 2877-2888
31. Zavada J Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54: 268-274 (Pubitemid 23154893)
32. Opavsky R, Pastorekova S, Zelnik Metal. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996; 33: 480-487
33. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-494 (Pubitemid 16006918)
34. Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. Int J Cancer 2000; 85: 865-870
35. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek K, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 1808-1813 (Pubitemid 30307393)
36. Dorai T Sawczuk IS, Pastorek J, Wiernik PH Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 41: 293547
37. Pastorekova S, Parkkila S, Parkkila AK et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112:398-408
38. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumorassociated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083
39. Kaluz S, Kaluzova M, Chrastina A et al. Lowered oxygen tension induces expression of the hypoxia marker MN/ carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res 2002; 62: 4469-4477 (Pubitemid 34827310)
40. Kopacek J, Barathova M, Dequiedt F et al. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta 2005; 1729: 41-49 (Pubitemid 40732423)
41. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459-468
42. Ivanov SV, Kuzmin I, Wei MH et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998; 95: 12596-12601 (Pubitemid 28483810)
43. Barathova M, Takacova M, Holotnakova T et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer 2008; 98: 129-136
44. Zatovicova M, Sedlakova O, Svastova E et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005; 93: 1267-1276 (Pubitemid 41679413)
45. Svastova E, Zilka N, Zatovicova M et al. Carbonic anhydrase IX reduces Ecadherin-mediated adhesion of MDCK cells via interaction with ß-catenin. Exp Cell Res 2002; 290: 332-345 (Pubitemid 37272176)
46. lnnocenti A, Vullo D, Scozzafava A, Casey JR, Supuran CT. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Medi Chem Lett 2005; 15: 573-578
47. Vince JW, Reithmeier RAF. Carbonic anhydrase ll binds to the carboxylterminus of human band 3, the erythrocyte CI-/HC03- exchanger. J Biol Chem 1998; 273: 28430-28437
48. McMurtrie HL, Geary HJ, Alvarez BV et al. The bicarbonate transport metabolon. J Enzyme lnhib Med Chem 2004; 19: 231-236
49. Svastova E, Hulikova A, Rafajova M et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-445 (Pubitemid 39535327)
50. Swietach P, Vaughan-Jones RD, Harris AL, Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26: 299310
51. Raghunand N, Gatenby RA, Gillies RJ, Microenvironmental and cellular consequences of altered blood flow in tumors. Br J Radiol 2003; 76: S11-22 (Pubitemid 39530312)
52. Robertson N, Potter C, Harris AL, Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004; 64: 6160-6165 (Pubitemid 39129417)
53. Morgan PE, Pastoreková S, StuartTilley AK, Alper SL, Casey JR, Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am J Physiol Cell Physiol 2007; 293: C738-48 (Pubitemid 47235179)
54. Cecchi A, Hulikova A, Pastorek J et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005; 48: 4834-4841 (Pubitemid 41033126)
55. Pastorekova S. Zavada J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Review article. Available at: http://www. cancertherapy.org. Accessed March 2008. Cancer Ther 2004; 2: 245-262
56. Pastorekova S, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007; 7: 865-878 (Pubitemid 46830331)
57. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004; 3: 164-167 (Pubitemid 40268690)
58. Zavada J, Zavadova Z, Zatovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003; 89: 1067-1071 (Pubitemid 37239213)
59. Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 34-41
60. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9: 4641-4652 (Pubitemid 37323266)
61. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Patents 2000; 10:575-600 (Pubitemid 30251754)
62. Supuran CT. Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 2007; 7: 825-833 (Pubitemid 46825080)
63. Vullo D, Scozzafava A, Pastorekova S, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg Med Chem Lett 2004; 14: 2351-2356 (Pubitemid 38481419)
64. Dubois L, Douma K, Supuran CT et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007; 83: 367-373 (Pubitemid 46915545)
65. Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004; 24: 995-1004
66. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem Lett 2001 ; 9: 703-714 (Pubitemid 32208589)
67. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling and approaches to enforce tumour regression. Nature 2006; 441: 437-443 (Pubitemid 44050138)
68. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549-1556